Goldman Sachs Group Inc Rubius Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	SELL	$0.14 - $0.31 $3,781 - $8,373	-27,010 Reduced 60.67%	17,511 $3,000
Q4 2022 Feb 13, 2023	SELL	$0.14 - $0.31 $3,781 - $8,373	-27,010 Reduced 60.67%	17,511 $3,000
Q3 2022 May 14, 2024	SELL	$0.46 - $1.29 $107,818 - $302,359	-234,387 Reduced 84.04%	44,521 $19,000
Q3 2022 Nov 10, 2022	SELL	$0.46 - $1.29 $107,818 - $302,359	-234,387 Reduced 84.04%	44,521 $0
Q2 2022 May 14, 2024	BUY	$0.79 - $5.98 $220,337 - $1.67 Million	278,908 New	278,908 $238,000
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $83,617 - $632,953	-105,845 Reduced 27.51%	278,908 $238,000
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $76,874 - $188,115	-18,088 Reduced 4.49%	384,753 $2.12 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $292,548 - $536,138	30,222 Added 8.11%	402,841 $3.9 Million
Q3 2021 Nov 10, 2021	BUY	$17.6 - $25.91 $6.56 Million - $9.65 Million	372,619 New	372,619 $6.66 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.